论文部分内容阅读
目的:探讨乳腺癌组织中抗凋亡基因Bcl-w的mRNA及蛋白表达情况及其临床意义。方法:采用real-time PCR及Western blotting等分子生物学技术对54例乳腺组织中的抗凋亡基因Bcl-w的mRNA及蛋白表达水平进行检测。结果:通过检测发现,临床各期乳腺癌组中Bcl-w基因mRNA表达水平均显著高于正常乳腺组(P<0.05),TNMⅣ期、Ⅲ期和Ⅱ期mRNA表达均高于Ⅰ期(P<0.05),TNMⅣ期、Ⅲ期和Ⅱ期之间Bcl-w基因mRNA表达差异无统计学意义(P>0.05);同时,临床各期乳腺癌组中Bcl-w蛋白表达水平均显著高于正常乳腺组(P<0.05),TNMⅣ期、Ⅲ期和Ⅱ期均高于Ⅰ期(P<0.05),TNMⅣ期、Ⅲ期和Ⅱ期之间Bcl-w蛋白表达无统计学差异(P>0.05)。结论:Bcl-w在乳腺癌发生发展过程中起着重要的抗凋亡作用,抑制Bcl-w表达水平可能作为新的治疗靶点。
Objective: To investigate the mRNA and protein expression of anti-apoptotic gene Bcl-w in breast cancer and its clinical significance. Methods: The mRNA and protein expressions of anti-apoptotic gene Bcl-w in 54 breast tissues were detected by real-time PCR and Western blotting. Results: The mRNA expression levels of Bcl-w in clinical breast cancer group were significantly higher than those in normal breast cancer group (P <0.05). The mRNA expressions of stage Ⅲ, Ⅲ and Ⅱ were higher than those in stage Ⅰ (P <0.05). There was no significant difference in the mRNA expression of Bcl-w between TNM stage Ⅳ, stage Ⅲ and stage Ⅱ (P> 0.05). Meanwhile, the expression levels of Bcl-w protein in breast cancer group were significantly higher than those in stage Ⅲ The expression of Bcl-w protein in TNM stage Ⅳ, stage Ⅲ, and stage Ⅱ was significantly higher than that in stage Ⅰ, stage Ⅲ, stage Ⅲ and stage Ⅲ (P <0.05) 0.05). CONCLUSION: Bcl-w plays an important anti-apoptotic role in the development of breast cancer. Inhibition of Bcl-w expression may be a new therapeutic target.